<DOC>
	<DOCNO>NCT01423305</DOCNO>
	<brief_summary>The objective study assess charcoal prevents absorption budesonide formoterol via GI track . The assessment base compare pharmacokinetic parameter area concentration-time curve .</brief_summary>
	<brief_title>Phase I Pharmacokinetic Study ( BF-BLOCK )</brief_title>
	<detailed_description />
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>1 . Healthy male female age 1860 year . 2 . Normal weight least 50 kg . 1 . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological psychiatric disease . 2 . Any clinically significant abnormal laboratory value physical finding may interfere interpretation study result constitute health risk subject he/she take part study . 3 . Any condition require concomitant treatment ( include vitamin herbal product ) likely need concomitant treatment study . 4 . Known hypersensitivity active substance ( ) excipients drug . 5 . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma</keyword>
</DOC>